MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7200
-0.1081
-13.05%
After Hours: 0.7226 +0.0026 +0.36% 16:06 04/01 EDT
OPEN
0.7750
PREV CLOSE
0.8281
HIGH
0.7949
LOW
0.7200
VOLUME
707.22K
TURNOVER
--
52 WEEK HIGH
1.670
52 WEEK LOW
0.5339
MARKET CAP
109.37M
P/E (TTM)
-16.1885
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LCTX stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.

EPS

LCTX News

More
  • Lineage Cell Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  • Zacks · 6d ago
  • Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
  • ACCESSWIRE · 03/24 21:00
  • Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/13 01:55
  • BioTime EPS beats by $0.03, beats on revenue
  • seekingalpha · 03/13 01:08

Industry

Biotechnology & Medical Research
-4.51%
Pharmaceuticals & Medical Research
-2.97%

Hot Stocks

Symbol
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.